AQX-435

AQX-435 (also known as AQX-C5) is a novel, orally bioavailable small molecule activator of the **Src homology domain 2-containing inositol-5'-phosphatase 1 (SHIP1)** enzyme. Developed by **Aquinox Pharmaceuticals**, it is primarily investigated for the treatment of B-cell neoplasms, including chronic lymphocytic leukemia (CLL) and diffuse large B-cell lymphoma (DLBCL). The compound functions by enhancing the activity of SHIP1, which serves as a negative regulator of the PI3K/Akt signaling pathway by dephosphorylating PI(3,4,5)P3 into PI(3,4)P2. This action inhibits B-cell receptor-mediated signaling and induces caspase-dependent apoptosis in malignant cells. Preclinical data suggests that AQX-435 can reduce lymphoma growth in xenograft models and exhibits synergistic activity when combined with BTK inhibitors such as ibrutinib.